氢溴酸伏硫西汀片

Search documents
华润双鹤:湘中制药氢溴酸伏硫西汀片获药品注册证书
news flash· 2025-06-05 08:54
Group 1 - The core point of the article is that China Resources Double Crane (华润双鹤) announced that its subsidiary, Xiangzhong Pharmaceutical, received a drug registration certificate from the National Medical Products Administration for Hydrobromide Vortioxetine Tablets, which are used to treat adult depression [1] - The drug has been under development since 2021 and is expected to be approved for market launch by May 27, 2025 [1] - The total research and development investment for the drug has reached 12.1484 million yuan [1] Group 2 - In 2023, the global sales revenue for the drug reached 1.999 billion USD, while the domestic market sales totaled 214 million yuan [1]